Published in Arthritis Res Ther on August 19, 2014
Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma. Sci Transl Med (2015) 1.61
Role and mechanism of vascular cell adhesion molecule-1 in the development of rheumatoid arthritis. Exp Ther Med (2015) 0.77
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum (2005) 3.17
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant (2010) 3.10
Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res (2008) 2.23
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis (2005) 2.11
Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res (1997) 2.11
Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol (2003) 2.07
Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag (2009) 1.76
Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol (2012) 1.69
Monocyte/macrophage regulation of vascular calcification in vitro. Circulation (2002) 1.67
Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis. J Intern Med (2009) 1.61
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens (2005) 1.42
Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. Circulation (2000) 1.36
The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. J Biol Chem (2008) 1.34
Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) (2008) 1.27
Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens (2010) 1.21
Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem Biophys Res Commun (1998) 1.13
Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo. J Clin Invest (2000) 1.11
Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol (2012) 1.05
Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology (1996) 1.02
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis (2008) 0.99
Agonist-driven maturation and plasma membrane insertion of calcium-sensing receptors dynamically control signal amplitude. Sci Signal (2011) 0.97
G-protein-coupled, extracellular Ca(2+)-sensing receptor: a versatile regulator of diverse cellular functions. Vitam Horm (1999) 0.97
Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. Cardiovasc Res (2013) 0.93
The calcium sensing receptor life cycle: trafficking, cell surface expression, and degradation. Best Pract Res Clin Endocrinol Metab (2013) 0.90
Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clin Res Cardiol (2013) 0.88
Expression of extracellular calcium (Ca2+o)-sensing receptor in human peripheral blood monocytes. Biochem Biophys Res Commun (1998) 0.88
Vascular calcification in rheumatoid arthritis: prevalence, pathophysiological aspects and potential targets. Atherosclerosis (2012) 0.79
Mortality in individuals without known coronary artery disease but with discordance between the Framingham risk score and coronary artery calcium. Am J Cardiol (2011) 0.79
Altered monocyte calcium-sensing receptor expression in patients with type 2 diabetes mellitus and atherosclerosis. J Physiol Pharmacol (2013) 0.78
Determination and modulation of total and surface calcium-sensing receptor expression in monocytes in vivo and in vitro. PLoS One (2013) 0.77
Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J (2007) 2.99
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol (2008) 2.96
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS (2011) 2.23
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int (2009) 1.93
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine (2012) 1.85
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine (2003) 1.59
Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation (2002) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol (2014) 1.51
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) (2009) 1.51
Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer. Br J Nutr (2007) 1.48
The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine (2007) 1.44
Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol (2013) 1.42
Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum (2002) 1.41
The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol (2010) 1.39
Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Nat Clin Pract Nephrol (2006) 1.39
Diagnosis of central hypovolemia by using passive leg raising. Intensive Care Med (2007) 1.39
Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int (2005) 1.33
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.26
The role of the calcium-sensing receptor in the development and progression of cancer. Endocr Rev (2009) 1.23
Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens (2010) 1.21
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res (2006) 1.20
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther (2009) 1.20
Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19
Calcium sensing receptor signalling in physiology and cancer. Biochim Biophys Acta (2012) 1.19
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol (2004) 1.16
The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem (2008) 1.14
Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant (2011) 1.12
Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res (2009) 1.10
Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol (2011) 1.10
Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine (2007) 1.10
High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol (2008) 1.09
Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology (2005) 1.08
Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol (2003) 1.08
Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J (2003) 1.07
p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol (2013) 1.04
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine (2007) 1.03
Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. Circulation (2008) 1.01
Radiographic methods for evaluating osteoporotic vertebral fractures. Joint Bone Spine (2009) 1.00
Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor. Exp Cell Res (2009) 1.00
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis (2008) 0.99
Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem (2004) 0.99
Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis (2005) 0.99
New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum (2011) 0.97
Osteoporosis and mortality. Joint Bone Spine (2010) 0.97
Agonists and allosteric modulators of the calcium-sensing receptor and their therapeutic applications. Mol Pharmacol (2009) 0.97
Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation. Cell Physiol Biochem (2009) 0.96
Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol (2007) 0.96
Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels. Ann Rheum Dis (2012) 0.95
Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. J Rheumatol (2006) 0.95
Indoxyl sulphate inhibits osteoclast differentiation and function. Nephrol Dial Transplant (2011) 0.95
The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant (2010) 0.94
Epidemiology of osteoporosis-related fractures in France: a literature review. Joint Bone Spine (2010) 0.94
Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. Cardiovasc Res (2013) 0.93
Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif (2010) 0.92
Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia. Nephrol Dial Transplant (2007) 0.92
Oxidized low density lipoprotein inhibits phosphate signaling and phosphate-induced mineralization in osteoblasts. Involvement of oxidative stress. Biochim Biophys Acta (2010) 0.91
Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab (2003) 0.91
A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine (2007) 0.90
Musculoskeletal ultrasonography in healthy subjects and ultrasound criteria for early arthritis (the ESPOIR cohort). J Rheumatol (2011) 0.89
Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS One (2012) 0.89
Serious spontaneous epistaxis and hypertension in hospitalized patients. Eur Arch Otorhinolaryngol (2011) 0.89
The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp Cell Res (2004) 0.89
Review on uraemic solutes II--variability in reported concentrations: causes and consequences. Nephrol Dial Transplant (2007) 0.89
Strontium ranelate decreases receptor activator of nuclear factor-ΚB ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor. Mol Pharmacol (2010) 0.88
Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. Mol Cell Endocrinol (2010) 0.88
Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine (2009) 0.88